Publikationen, an denen er mitarbeitet Jackeline Agorreta Arrazubi (43)

2022

  1. DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity

    The Journal of experimental medicine, Vol. 219, Núm. 12

  2. Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 1

2021

  1. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

2020

  1. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas

    Cancer Immunology, Immunotherapy, Vol. 69, Núm. 10, pp. 2089-2100

2019

  1. 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging

    Thorax, Vol. 74, Núm. 4, pp. 371-379

  2. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

    International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001

  3. The SRC inhibitor dasatinib induces stem cell-like properties in head and neck cancer cells that are effectively counteracted by the mithralog EC-8042

    Journal of Clinical Medicine, Vol. 8, Núm. 8

  4. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2018

  1. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients

    Journal of Pathology, Vol. 245, Núm. 4, pp. 421-432

  2. Blockade of the complement C5a/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects

    American Journal of Respiratory and Critical Care Medicine, Vol. 197, Núm. 9, pp. 1164-1176

  3. Complement C4d-specific antibodies for the diagnosis of lung cancer

    Oncotarget, Vol. 9, Núm. 5, pp. 6346-6355

  4. The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer

    Laboratory Investigation, Vol. 98, Núm. 12, pp. 1562-1574

  5. The sVEGFR1-i13 splice variant regulates a β1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma

    British Journal of Cancer, Vol. 118, Núm. 12, pp. 1596-1608

2017

  1. A combined PD-1/C5a blockade synergistically protects against lung cancer growth and metastasis

    Cancer Discovery, Vol. 7, Núm. 7, pp. 694-703

  2. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer

    Cancer Discovery, Vol. 7, Núm. 12, pp. 1420-1435

2016

  1. Successful immunotherapy against a transplantable mouse squamous lung carcinoma with anti-PD-1 and anti-CD137 monoclonal antibodies

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. 524-536

2015

  1. Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations

    BMC Genomics, Vol. 16, Núm. 1

  2. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients

    PLoS ONE, Vol. 10, Núm. 4

  3. Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism-related genes

    Journal of Thoracic and Cardiovascular Surgery, Vol. 150, Núm. 4, pp. 986-992.e11

2014

  1. Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype

    EMBO Molecular Medicine, Vol. 6, Núm. 4, pp. 539-550